Selank
Selank • Also called Selank Acetate, TP-7
Selank is a calming and cognitive peptide with strong online demand, but the FDA posture still leaves it in a grey zone for pharmacies.
Current status
Under Review
Calming and cognitive interest, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Often discussed together with Semax, though Selank has the cleaner near-term review story.
Primary Use
Calming and cognitive interest
Also searched as
Selank Acetate, TP-7
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 19, 2024
Current status signal recorded: PCAC review status replaced the earlier Category 2 treatment..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Selank status changes
State-specific notes
Florida
Interest is strong but compliant supply remains uneven.